5 Liver Cancer News and Updates That Patients May Have Missed in 2020

January 7, 2021
Ryan McDonald

A roundup of liver cancer news and updates that occurred in 2020 patients with cancer may have missed.

There were several updates in the field of liver cancer in 2020. Here, CURE® looks back at some news and updates in the field of liver cancer that patients may have missed.

  • Treatment with Opdivo (nivolumab) with Yervoy (ipilimumab) was manageably safe and resulted in a promising response in patients with advanced hepatocellular carcinoma (HCC) previously treated with Nexavar (sorafenib). READ MORE.
  • The combination of Tafinlar (dabrafenib) plus Mekinist (trametinib) could offer patients with BRAF V600E-mutated biliary tract cancer another much-needed treatment option, according to results from a phase 2 study published in the Lancet Oncology. READ MORE.
  • A survey administered by pharmaceutical company Incyte and the nonprofit Cholangiocarcinoma Foundation found that patients with bile duct cancer face more than a dozen symptoms or treatment-related side effects that negatively affect their daily lives. READ MORE.
  • The Food and Drug Administration’s approval of Pemazyre (pemigatinib) in May was a “huge milestone” for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation. READ MORE.
  • Racial inequities in the liver cancer death rate, which previously had been declining, started rising after lifesaving drugs became available to treat hepatitis C virus, a major risk factor for the cancer. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.